CLINICAL TRIALS PROFILE FOR ZONEGRAN
✉ Email this page to a colleague
All Clinical Trials for ZONEGRAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00056576 ↗ | Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy | Completed | Eisai Inc. | Phase 3 | 2002-02-01 | The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases. |
| NCT00154076 ↗ | A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies | Completed | Eisai Korea Inc. | Phase 4 | 2005-09-01 | To assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies |
| NCT00165828 ↗ | Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization | Terminated | Eisai GmbH | Phase 4 | 2005-05-01 | Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50 mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control assessments are performed at the beginning of the study and at the end of the prospective baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first, second, and third treatment week, and at the end of week six, the patient is additionally contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all control visits, and at the end of the study. |
| NCT00203450 ↗ | Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial | Completed | Eisai Inc. | Phase 4 | 2003-05-01 | The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain. |
| NCT00203450 ↗ | Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial | Completed | Tuscaloosa Research & Education Advancement Corporation | Phase 4 | 2003-05-01 | The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain. |
| NCT00215592 ↗ | Open Label, Zonegran (Zonisamide) In Partial Onset Seizures | Completed | Eisai Limited | Phase 4 | 2005-10-01 | To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZONEGRAN
Condition Name
Clinical Trial Locations for ZONEGRAN
Trials by Country
Clinical Trial Progress for ZONEGRAN
Clinical Trial Phase
Clinical Trial Sponsors for ZONEGRAN
Sponsor Name
